Can you tell us a bit more about the aims and history of Bioelectronic Medicine?
The field of bioelectronic medicine comprises basic research identifying the mechanisms of neural regulation and their translation into new treatments for many diseases and conditions, such as rheumatoid arthritis, diabetes, and paralyses.
The first successful examples of this translational approach are the recent clinical trials with vagus nerve stimulation in patients with rheumatoid arthritis and inflammatory bowel disease. The team-based efforts of immunologists, neuroscientists, bioengineers, computational scientists and many others have been instrumental for the current success of the field.
The Feinstein Institute for Medical Research established Bioelectronic Medicine to provide a platform for publishing new discoveries in this emerging and rapidly evolving field. We believe Bioelectronic Medicine will continue to be an engaging forum for sharing novel ideas and multidisciplinary discussions on the development of new disease treatments based on neuromodulation.
What made you choose BMC as a publishing partner?
We have experienced tremendous growth since we launched our flagship journal, Molecular Medicine, over 20 years ago. We began publishing Bioelectronic Medicine in 2014 as an open access journal. We chose BMC as our partner because of their strong tradition in delivering open access content and their best-in-class publishing mechanisms and strategies.
What is your vision for the future of Bioelectronic Medicine?
Bioelectronic Medicine will become the leader in publishing the latest advances in the exploration of cutting edge technology to map neural circuits, elucidate neural alterations in disease conditions, and modulate discrete neural pathways for therapeutic benefit. The success of the journal is interrelated with the success of the field, which we believe will transform medicine.